Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels

Figure 1 Fecal calprotectin levels at baseline, and 2 and 6 wk after introduction of infliximab therapy in children with Crohn’s disease or ulcerative colitis. The decline in levels between baseline and week 2 was statistically significant (P < 0.001). CD: Crohn’s disease; UC: Ulcerative colitis.

Figure 2 Fecal calprotectin levels at baseline, and 2 and 6 wk after introduction of infliximab therapy showing the individual variation in children with inflammatory bowel disease.